The present adenomyosis treatment status in Luzhou, China: a small scope observational cross-sectional survey
Abstract Objective To evaluate the current treatment status and management deficiencies of adenomyosis in Luzhou, China. Materials and methods A small-scale observational cross-sectional study of patients whose imaging suggests adenomyosis from July 2018 to February 2022 at a teaching hospital in Lu...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-02-01
|
| Series: | BMC Women's Health |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12905-025-03619-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850185288880488448 |
|---|---|
| author | Lingling Xie Mengsi Yang Xinyu Chen Luxia Yao Wei Xu Qiuling Shi Yuan Yuan |
| author_facet | Lingling Xie Mengsi Yang Xinyu Chen Luxia Yao Wei Xu Qiuling Shi Yuan Yuan |
| author_sort | Lingling Xie |
| collection | DOAJ |
| description | Abstract Objective To evaluate the current treatment status and management deficiencies of adenomyosis in Luzhou, China. Materials and methods A small-scale observational cross-sectional study of patients whose imaging suggests adenomyosis from July 2018 to February 2022 at a teaching hospital in Luzhou, China. All participants (1542 patients) completed a questionnaire of 14 items, including basic information, symptoms, treatment options, outcomes, and costs. The patients’ treatment options and the hysterectomy rate were evaluated. Results The treatment options of hormone agents included combined oral contraceptive pills (COCs), gonadotropin-releasing hormone analogues (GnRH-a), levonorgestrel-releasing intrauterine system (LNG-IUS), and dienogest for 2.07, 46.04, 63.49, and 4.67% of patients, respectively. The treatment options under uterus-sparing surgery included adenomyectomy and high-intensity focused ultrasound (HIFU) treatment, presenting in 3.76 and 33.27% of patients, respectively. Finally, 458 (29.70%) patients chose a hysterectomy. The hysterectomy rate between the hormone and uterus-sparing surgery sequential hormone groups (surgery group) was not significantly different (14.8 vs. 12.7%, χ2 = 0.344, P > 0.05). However, for the focal type and patients with > 24 months delayed treatment interval, the hysterectomy rate of the hormone group was significantly higher than that of the surgery group (8.5% vs. 1.3%, χ2 = 11.722, P < 0.01 and 26.7% vs. 18.5%, χ2 = 4.906, P < 0.05, respectively). Conclusions There were treatment delays and treatment selection bias in managing adenomyosis in Luzhou, China. Popular science education and early individualized hormone therapy are needed. Uterine-sparing surgery should be carefully selected. |
| format | Article |
| id | doaj-art-cf069a2fc9b04d3498d94e8b948ae5af |
| institution | OA Journals |
| issn | 1472-6874 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Women's Health |
| spelling | doaj-art-cf069a2fc9b04d3498d94e8b948ae5af2025-08-20T02:16:46ZengBMCBMC Women's Health1472-68742025-02-012511810.1186/s12905-025-03619-0The present adenomyosis treatment status in Luzhou, China: a small scope observational cross-sectional surveyLingling Xie0Mengsi Yang1Xinyu Chen2Luxia Yao3Wei Xu4Qiuling Shi5Yuan Yuan6Sichuan Provincial Center for Gynaecology and Breast Diseases, The Affiliated Hospital of Southwest Medical UniversityClinical medical college, Southwest Medical UniversityClinical medical college, Southwest Medical UniversityClinical medical college, Southwest Medical UniversitySchool of Public Health and Management, Chongqing Medical UniversityState Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical UniversitySichuan Provincial Center for Gynaecology and Breast Diseases, The Affiliated Hospital of Southwest Medical UniversityAbstract Objective To evaluate the current treatment status and management deficiencies of adenomyosis in Luzhou, China. Materials and methods A small-scale observational cross-sectional study of patients whose imaging suggests adenomyosis from July 2018 to February 2022 at a teaching hospital in Luzhou, China. All participants (1542 patients) completed a questionnaire of 14 items, including basic information, symptoms, treatment options, outcomes, and costs. The patients’ treatment options and the hysterectomy rate were evaluated. Results The treatment options of hormone agents included combined oral contraceptive pills (COCs), gonadotropin-releasing hormone analogues (GnRH-a), levonorgestrel-releasing intrauterine system (LNG-IUS), and dienogest for 2.07, 46.04, 63.49, and 4.67% of patients, respectively. The treatment options under uterus-sparing surgery included adenomyectomy and high-intensity focused ultrasound (HIFU) treatment, presenting in 3.76 and 33.27% of patients, respectively. Finally, 458 (29.70%) patients chose a hysterectomy. The hysterectomy rate between the hormone and uterus-sparing surgery sequential hormone groups (surgery group) was not significantly different (14.8 vs. 12.7%, χ2 = 0.344, P > 0.05). However, for the focal type and patients with > 24 months delayed treatment interval, the hysterectomy rate of the hormone group was significantly higher than that of the surgery group (8.5% vs. 1.3%, χ2 = 11.722, P < 0.01 and 26.7% vs. 18.5%, χ2 = 4.906, P < 0.05, respectively). Conclusions There were treatment delays and treatment selection bias in managing adenomyosis in Luzhou, China. Popular science education and early individualized hormone therapy are needed. Uterine-sparing surgery should be carefully selected.https://doi.org/10.1186/s12905-025-03619-0AdenomyosisAdenomyectomyHigh-intensity focused ultrasoundHysterectomyHormone |
| spellingShingle | Lingling Xie Mengsi Yang Xinyu Chen Luxia Yao Wei Xu Qiuling Shi Yuan Yuan The present adenomyosis treatment status in Luzhou, China: a small scope observational cross-sectional survey BMC Women's Health Adenomyosis Adenomyectomy High-intensity focused ultrasound Hysterectomy Hormone |
| title | The present adenomyosis treatment status in Luzhou, China: a small scope observational cross-sectional survey |
| title_full | The present adenomyosis treatment status in Luzhou, China: a small scope observational cross-sectional survey |
| title_fullStr | The present adenomyosis treatment status in Luzhou, China: a small scope observational cross-sectional survey |
| title_full_unstemmed | The present adenomyosis treatment status in Luzhou, China: a small scope observational cross-sectional survey |
| title_short | The present adenomyosis treatment status in Luzhou, China: a small scope observational cross-sectional survey |
| title_sort | present adenomyosis treatment status in luzhou china a small scope observational cross sectional survey |
| topic | Adenomyosis Adenomyectomy High-intensity focused ultrasound Hysterectomy Hormone |
| url | https://doi.org/10.1186/s12905-025-03619-0 |
| work_keys_str_mv | AT linglingxie thepresentadenomyosistreatmentstatusinluzhouchinaasmallscopeobservationalcrosssectionalsurvey AT mengsiyang thepresentadenomyosistreatmentstatusinluzhouchinaasmallscopeobservationalcrosssectionalsurvey AT xinyuchen thepresentadenomyosistreatmentstatusinluzhouchinaasmallscopeobservationalcrosssectionalsurvey AT luxiayao thepresentadenomyosistreatmentstatusinluzhouchinaasmallscopeobservationalcrosssectionalsurvey AT weixu thepresentadenomyosistreatmentstatusinluzhouchinaasmallscopeobservationalcrosssectionalsurvey AT qiulingshi thepresentadenomyosistreatmentstatusinluzhouchinaasmallscopeobservationalcrosssectionalsurvey AT yuanyuan thepresentadenomyosistreatmentstatusinluzhouchinaasmallscopeobservationalcrosssectionalsurvey AT linglingxie presentadenomyosistreatmentstatusinluzhouchinaasmallscopeobservationalcrosssectionalsurvey AT mengsiyang presentadenomyosistreatmentstatusinluzhouchinaasmallscopeobservationalcrosssectionalsurvey AT xinyuchen presentadenomyosistreatmentstatusinluzhouchinaasmallscopeobservationalcrosssectionalsurvey AT luxiayao presentadenomyosistreatmentstatusinluzhouchinaasmallscopeobservationalcrosssectionalsurvey AT weixu presentadenomyosistreatmentstatusinluzhouchinaasmallscopeobservationalcrosssectionalsurvey AT qiulingshi presentadenomyosistreatmentstatusinluzhouchinaasmallscopeobservationalcrosssectionalsurvey AT yuanyuan presentadenomyosistreatmentstatusinluzhouchinaasmallscopeobservationalcrosssectionalsurvey |